We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 25, 2022

18F-NaF PET-CT vs 99mTc-MDP SPECT for Detecting Bone Metastasis in Patients With High-Risk Prostate or Breast Cancer

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial
Lancet Oncol 2022 Nov 04;[EPub Ahead of Print], F Bénard, S Harsini, D Wilson, K Zukotynski, G Abikhzer, E Turcotte, M Cossette, U Metser, J Romsa, M Martin, C Mar, F Saad, JP Soucy, BJ Eigl, P Black, A Krauze, S Burrell, A Nichol, JC Tardif

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading